Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating progress in its oncology treatment pipeline [1] Group 1: Drug Approvals - Jiangsu Heng Rui Medicine Co., Ltd. and its subsidiaries have been granted clinical trial approval for SHR-4394, HRS-5041 tablets, Zemeituo Sita tablets (SHR-2554), and Ruvelamine tablets [1] - The approval is based on compliance with the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1] Group 2: Clinical Trials - The clinical trials will focus on the safety, tolerability, and efficacy of SHR-4394 or HRS-5041 in combination with anti-tumor treatment in participants with prostate cancer [1] - The trials are categorized as multi-center and open-label Phase II studies [1]